| |
Iridium brachytherapy plus surgery in canine mast cell tumors
 |
Cutaneous mast cell tumors in dogs are frequently seen. Although different therapeutic regimen are described, the results are often not satisfactory. This retrospective study describes a new therapy, a combination of Iridium radiotherapy and surgery. Is this the new therapy of choice?
|
|
|
| |
Eleven dogs with cutaneous mast cell tumors (MCTs) were treated with surgery and iridium-192 (192Ir) interstitial brachytherapy.
Minimum tumor doses ranged from 47.2 to 63.3 Gy. Treated tumors were classified as grade II (n=7) or III (n=4).
Five dogs had recurrences with a median progression-free interval of 1391 days, and six dogs had no recurrence at a median follow-up time of 942 days.
Acute adverse effects were well tolerated, and late effects were mild. One dog developed a second tumor of a different cell type in the radiation treatment field.
Source: Nicole C. Northrup, Royce E. Roberts, Todd W. Harrell, Karen L. Allen, Elizabeth W. Howerth, Tracy L. Gieger (2004): Iridium-192 Interstitial Brachytherapy as Adjunctive Treatment for Canine Cutaneous Mast Cell Tumors. In: Journal of the American Animal Hospital Association 40:309-315 (2004)
Tell a friend
|
Print version
|
Send this article
|
| |
Metastasis of a well differentiated perianal gland tumorPunica granatum associated with hepatotoxicosis in cattle Toceranib phosphate (Palladia®) in canine gastrointestinal stromal tumorsRadioactive iodine uptake in hyperthyroid cats after rh-TSHHypoechoic tissue changes in dogs with malignant prostatic lymphomaEmphysematous gastritis in dogs and catsPrimary pulmonary histiocytic sarcoma in dogsDetermining prognosis in canine sepsis Correlation of plasma and tear glucose, creatinine and urea nitrogen in catsPerineal hernias in dogs - always a bilateral problem?Pharmacokinetic of gabapentin in catsFollicular development of canine ovaries stimulated by eCG plus hCG
|
